TY - JOUR
T1 - Transcriptomic Analysis Reveals the MicroRNAs Responsible for Liver Regeneration Associated With Mortality in Alcohol-Associated Hepatitis
AU - Yang, Zhihong
AU - Zhang, Ting
AU - Kusumanchi, Praveen
AU - Tang, Qing
AU - Sun, Zhaoli
AU - Radaeva, Svetlana
AU - Peiffer, Brandon
AU - Shah, Vijay H.
AU - Kamath, Patrick
AU - Gores, Greg J.
AU - Sanyal, Arun
AU - Chalasani, Naga
AU - Jiang, Yanchao
AU - Huda, Nazmul
AU - Ma, Jing
AU - Liangpunsakul, Suthat
N1 - Funding Information:
Supported by The Translational Research and Evolving Alcoholic Hepatitis Treatment (TREAT) Consortium, which is supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA; grants 5U01AA021883‐04, 5U01AA021891‐04, 5U01AA021788‐04, and 5U01AA021840‐04) and partly supported by R01DK107682, R01AA025208, U01 AA026917, UH2/UH3 AA026903, U01AA026817, I01CX000361, Showalter Scholar, and Dean’s Scholar for Medical Research (to S.L.); and K01 AA026385 and the Ralph W. and Grace M. Showalter Research Trust (to Z.Y.).
Funding Information:
The TREAT (Translational Research and Evolving Alcoholic hepatitis Treatment) consortium, consisting of Indiana University, Virginia Commonwealth University, and Mayo Clinic, is supported by the National Institute of Alcohol Abuse and Alcoholism (NIAAA). Its primary objectives are to conduct clinical research in AH and develop treatments. As part of the research protocol, a prospective, multicenter, observational study of patients with well‐characterized AH (cases) and heavy drinkers (HDs) without evidence of liver disease (controls) was conducted. Serum samples were collected at baseline, and patients were prospectively followed for up to 12 months. The objectives of our study were to (1) explore differentially expressed serum miRNAs and their targets in a well‐characterized cohort of patients with AH, (2) identify the potential miRNA‐based mechanism underlying the pathogenesis of AH, and (3) determine the prognostic significance of miRNAs and outcomes in patients with AH.
Publisher Copyright:
© 2021 by the American Association for the Study of Liver Diseases.
PY - 2021/11
Y1 - 2021/11
N2 - Background and Aims: We conducted a comprehensive serum transcriptomic analysis to explore the roles of microRNAs (miRNAs) in alcohol-associated hepatitis (AH) pathogenesis and their prognostic significance. Approach and Results: Serum miRNA profiling was performed in 15 controls, 20 heavy drinkers without liver disease, and 65 patients with AH and compared to publicly available hepatic miRNA profiling in AH patients. Among the top 26 miRNAs, expression of miR-30b-5p, miR-20a-5p, miR-146a-5p, and miR-26b-5p were significantly reduced in both serum and liver of AH patients. Pathway analysis of the potential targets of these miRNAs uncovered the genes related to DNA synthesis and cell-cycle progression pathways, including ribonucleotide reductase regulatory subunit M2 (RRM2), cyclin D1 (CCND1), cyclin D2 (CCND2), MYC proto-oncogene (MYC), and phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1). We found a significant increase in the protein expression of RRM2, CCND1, and CCND2, but not MYC and PMAIP1, in AH patients who underwent liver transplantation; miR-26b-5p and miR-30b-5p inhibited the 3′-UTR (untranslated region) luciferase activity of RRM2 and CCND2, and miR-20a-5p reduced the 3′-UTR luciferase activity of CCND1 and CCND2. During a median follow-up of 346 days, 21% of AH patients died; these patients had higher body mass index (BMI), Model for End-Stage Liver Disease (MELD), and serum miR-30b-5p, miR-20a-5p, miR-146a-5p, and miR-26b-5p than those who survived. Cox regression analysis showed that BMI, MELD score, miR-20a-5p, miR-146a-5p, and miR-26b-5p predicted mortality. Conclusions: Patients with AH attempt to deal with hepatocyte injury by down-regulating specific miRNAs and up-regulating genes responsible for DNA synthesis and cell-cycle progression. Higher expression of these miRNAs, suggestive of a diminished capacity in liver regeneration, predicts short-term mortality in AH patients.
AB - Background and Aims: We conducted a comprehensive serum transcriptomic analysis to explore the roles of microRNAs (miRNAs) in alcohol-associated hepatitis (AH) pathogenesis and their prognostic significance. Approach and Results: Serum miRNA profiling was performed in 15 controls, 20 heavy drinkers without liver disease, and 65 patients with AH and compared to publicly available hepatic miRNA profiling in AH patients. Among the top 26 miRNAs, expression of miR-30b-5p, miR-20a-5p, miR-146a-5p, and miR-26b-5p were significantly reduced in both serum and liver of AH patients. Pathway analysis of the potential targets of these miRNAs uncovered the genes related to DNA synthesis and cell-cycle progression pathways, including ribonucleotide reductase regulatory subunit M2 (RRM2), cyclin D1 (CCND1), cyclin D2 (CCND2), MYC proto-oncogene (MYC), and phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1). We found a significant increase in the protein expression of RRM2, CCND1, and CCND2, but not MYC and PMAIP1, in AH patients who underwent liver transplantation; miR-26b-5p and miR-30b-5p inhibited the 3′-UTR (untranslated region) luciferase activity of RRM2 and CCND2, and miR-20a-5p reduced the 3′-UTR luciferase activity of CCND1 and CCND2. During a median follow-up of 346 days, 21% of AH patients died; these patients had higher body mass index (BMI), Model for End-Stage Liver Disease (MELD), and serum miR-30b-5p, miR-20a-5p, miR-146a-5p, and miR-26b-5p than those who survived. Cox regression analysis showed that BMI, MELD score, miR-20a-5p, miR-146a-5p, and miR-26b-5p predicted mortality. Conclusions: Patients with AH attempt to deal with hepatocyte injury by down-regulating specific miRNAs and up-regulating genes responsible for DNA synthesis and cell-cycle progression. Higher expression of these miRNAs, suggestive of a diminished capacity in liver regeneration, predicts short-term mortality in AH patients.
UR - http://www.scopus.com/inward/record.url?scp=85111581861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111581861&partnerID=8YFLogxK
U2 - 10.1002/hep.31994
DO - 10.1002/hep.31994
M3 - Article
C2 - 34096637
AN - SCOPUS:85111581861
SN - 0270-9139
VL - 74
SP - 2436
EP - 2451
JO - Hepatology
JF - Hepatology
IS - 5
ER -